Becton, Dickinson and Company has acquired Edwards Lifesciences’ critical care product group. The addition will be renamed BD Advanced Patient Monitoring.
The medical technology company’s new business unit includes AI-enabled products, BD said in a Sept. 3 news release. The acquisition of California-based Edwards Lifesciences cost $4.2 billion.
Katie Szyman, who has served as corporate vice president of the business under Edwards since 2015, is now worldwide president of BD Advanced Patient Monitoring.
President Donald Trump has threatened tariffs on pharmaceutical imports, with U.S. Commerce Secretary Howard Lutnick confirming that the tariffs will…
China imposed 125% tariffs on U.S. goods in retaliation to President Donald Trump imposing a 145% tariff rate on Chinese…
Novartis plans to invest $23 billion over the next five years to expand its manufacturing and research in the U.S. …
Comments are closed.
